BioSenic S.A. Asset Resilience Ratio
BioSenic S.A. asset resilience ratio. BioSenic S.A. (BIOS) has an Asset Resilience Ratio of -3.43% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BioSenic S.A. (BIOS) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BioSenic S.A. (2011–2023)
Asset resilience ratio of BioSenic S.A. from 2011 to 2023. This chart shows how BioSenic S.A.'s Asset Resilience Ratio has changed over time. Read BioSenic S.A. total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BioSenic S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BIOS current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €-322.00K | -3.43% |
| Total Liquid Assets | €-322.00K | -3.43% |
Asset Resilience Insights
- Limited Liquidity: BioSenic S.A. maintains only -3.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
BioSenic S.A. Industry Peers by Asset Resilience Ratio
Compare BioSenic S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
BioSenic S.A. Asset Resilience Ratio by Year (2011–2023)
BioSenic S.A. asset resilience ratio by year from 2011 to 2023. The table below shows the annual Asset Resilience Ratio data for BioSenic S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 4.16% | €398.00K ≈ $465.30K |
€9.56 Million ≈ $11.18 Million |
+4.54pp |
| 2022-12-31 | -0.38% | €-111.00K ≈ $-129.77K |
€29.32 Million ≈ $34.28 Million |
-6.45pp |
| 2021-12-31 | 6.07% | €1.20 Million ≈ $1.40 Million |
€19.77 Million ≈ $23.12 Million |
+6.69pp |
| 2019-12-31 | -0.63% | €-140.00K ≈ $-163.67K |
€22.39 Million ≈ $26.18 Million |
-1.97pp |
| 2011-12-31 | 1.35% | €203.00K ≈ $237.33K |
€15.05 Million ≈ $17.60 Million |
-- |
About BioSenic S.A.
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more